Phase I trial of cremophor EL with bolus doxorubicin.

Autor: Millward MJ; Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia. michaelm@canc.rpa.cs.nsw.gov.au, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 1998 Oct; Vol. 4 (10), pp. 2321-9.

Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors.

Autor: Kober, Luisa¹ (AUTHOR), Schleser, Sebastian W.¹ (AUTHOR), Bär, Sofia I.¹ (AUTHOR), Schobert, Rainer¹ (AUTHOR) Rainer.Schobert@uni-bayreuth.de

Publikováno v: Journal of Biological Inorganic Chemistry (JBIC). Dec2022, Vol. 27 Issue 8, p731-745. 15p.

Pharmacokinetic modulation of substrate drugs via the inhibition of drug-metabolizing enzymes and transporters using pharmaceutical excipients.

Autor: Choi, Min-Koo, Lee, Jihoon, Song, Im-Sook

Publikováno v: Journal of Pharmaceutical Investigation (2093-5552); Jan2023, Vol. 53 Issue 1, p1-18, 18p

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.

Autor: Doz, F, Gentet, J C, Pein, F, Frappaz, D, Chastagner, P, Moretti, S, Vassal, G, Arditti, J, Tellingen, O Van, Iliadis, A, Catalin, J

Publikováno v: British Journal of Cancer. 3/1/2001, Vol. 84 Issue 5, p604. 7p.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Autor: Tellingen, O van, Huizing, M T, Panday, V R Nannan, Schellens, J H M, Nooijen, W J, Beijnen, J H

Publikováno v: British Journal of Cancer. 9/15/99, Vol. 81 Issue 2, p330. 6p.